Summary
Below-the knee critical limb ischemia (BTK-CLI) is the severe blockage of the arteries in the limb, leading to reduced blood flow. This condition currently affects over +3.5M people in the EU and US. The current standard of care for BTK-CLI is balloon angioplasty. This treatment unfortunately has failed to show strong clinical outcomes: around 40% of patients suffer from procedural complications, 73% of the cases develop restenosis within 3 months and 25% of patients end up requiring minor or major limb amputations. STENTiT has developed a first-in-class stent with regenerative capacity, a paradigm shift for medical stents. The Regenerative Stent is fully composed of nanofibers which allows for unique vascular restoration. The stent gradually dissolves while new vascular tissue is being formed, fully rebuilding the artery to secure long-term patency. STENTiT requests a €2.5M grant and €10M in equity to complete the clinical studies and prepare the Regenerative Stent for market launch.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/190170592 |
Start date: | 01-09-2023 |
End date: | 31-08-2025 |
Total budget - Public funding: | 4 901 667,50 Euro - 2 500 000,00 Euro |
Cordis data
Original description
Below-the knee critical limb ischemia (BTK-CLI) is the severe blockage of the arteries in the limb, leading to reduced blood flow. This condition currently affects over +3.5M people in the EU and US. The current standard of care for BTK-CLI is balloon angioplasty. This treatment unfortunately has failed to show strong clinical outcomes: around 40% of patients suffer from procedural complications, 73% of the cases develop restenosis within 3 months and 25% of patients end up requiring minor or major limb amputations. STENTiT has developed a first-in-class stent with regenerative capacity, a paradigm shift for medical stents. The Regenerative Stent is fully composed of nanofibers which allows for unique vascular restoration. The stent gradually dissolves while new vascular tissue is being formed, fully rebuilding the artery to secure long-term patency. STENTiT requests a €2.5M grant and €10M in equity to complete the clinical studies and prepare the Regenerative Stent for market launch.Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)